Key Quantitative Figures and Clinical Data

  • Trial Phase: Phase 1/2 study (JBI-802-02; ACTRN12624000478516; NCT07612280)
  • Patient Data Cut-off: June 30, 2026
  • Dosage: 15 mg
  • Patient Response: All 8 patients who initiated treatment at 15 mg achieved a >50% platelet reduction or platelet normalization (<400 ×10⁹/L) by Week 3.
  • Response Time: Median time to response was 15 days.
  • Durability: Platelet normalization was maintained through 33, 44, and 46 weeks in patients with >12 weeks of follow-up.
  • Leukocytosis Response: 7 of 11 patients with leukocytosis at 15 mg achieved a complete hematologic response.
  • Tolerability: No dose-limiting toxicities were observed at 5 mg, 7 mg, or 15 mg doses.

Dates of Action and Events

  • Disclosure Date: November 10, 2026, at 20:01 PM IST
  • ASH Annual Meeting Dates: December 12–15, 2026
  • Oral Presentation: December 14, 2026, at 5:15 p.m. CT / 6:15 p.m. ET (Abstract #1036)
  • Poster Presentation: December 14, 2026, at 6:00–8:00 p.m. CT / 7:00–9:00 p.m. ET (Abstract #5540)
  • Corporate Event: December 14, 2026, following the oral presentation

Parties Involved

  • Disclosing Entity: Jubilant Pharmova Limited (Scrip Code: 530019, Symbol: JUBLPHARMA)
  • Subject Company: Jubilant Therapeutics, Inc. (described as a step-down subsidiary)
  • Regulatory References: SEBI Listing Regulations, Regulation 30
  • Key Personnel:
  • Daniel O'Connor, President and Chief Executive Officer of Jubilant Therapeutics
  • Andrew McQuillan, MBBS, FRACP, FRCPA (Oral Presenter)
  • Sridharan Rajagopal, Ph.D. (Poster Presenter)
  • Naresh Kapoor, Company Secretary of Jubilant Pharmova Limited (signatory)
  • Conference: 68th American Society of Hematology (ASH) Annual Meeting and Exposition
  • External Contacts:
  • Investor Relations: Mike Moyer, LifeSci Advisors
  • Media Relations: Kendy Guarinoni, PhD, LifeSci Communications

Product and Trial Details

  • Drug Candidate: JBI-802, an orally administered dual inhibitor of LSD1 and HDAC6 (CoREST complex)
  • Indications: Essential thrombocythemia (ET), polycythemia vera (PV), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) with thrombocytosis
  • Patient Profile: Patients who were relapsed, refractory, or intolerant to standard of care
  • Study Design: Open-label, multicenter trial evaluating safety, tolerability, and preliminary efficacy
  • Mechanism of Action: Targets abnormal megakaryocyte differentiation, platelet production, leukocyte proliferation, and inflammatory signaling

Additional Corporate Information

  • The press release and related documents will be posted on the company's website at www.jubilantpharmova.com.
  • Jubilant Therapeutics will host a livestreamed event titled "Dual LSD1/HDAC6 Inhibition with JBI-802 in Thrombocytosis-Predominant MPN: Clinical Data and Emerging Perspectives" on December 14, 2026.
  • A replay of the event will be available on the Company's website (www.jubilanttx.com).
  • The company's pipeline includes JBI-3041, a selective first-in-class PAD4 inhibitor for autoimmune diseases.

Forward-Looking Statements

The disclosure contains standard forward-looking statements regarding clinical development, timing of data presentations, and drug potential, noting they are subject to risks and uncertainties including clinical development risks, preliminary nature of early-phase data, regulatory review, and execution risks.